%D8%A5%D9%8A%D9%86%D8%AA%D9%8A%D9%83%D8%A7%D9%81%D9%8A%D8%B1%D8%A7%D9%86%DA%A9%D8%A7%D9%88%DB%8C%D8%B1Category:EntecavirEntecavirEntecavirEntecavirEntekaviiri%D4%B7%D5%B6%D5%BF%D5%A5%D5%AF%D5%A1%D5%BE%D5%AB%D6%80EntecavirEntecavir%E3%82%A8%E3%83%B3%E3%83%86%E3%82%AB%E3%83%93%E3%83%AB%E0%AC%8F%E0%AC%A3%E0%AD%8D%E0%AC%9F%E0%AD%87%E0%AC%95%E0%AC%BE%E0%AC%AD%E0%AC%BF%E0%AC%B0EntekawirEntekavirEntekavirEntekavir%D0%95%D0%BD%D1%82%D0%B5%D0%BA%D0%B0%D0%B2%D1%96%D1%80EntecavirQ418586%E6%81%A9%E6%9B%BF%E5%8D%A1%E9%9F%A6
about
Drug Drug Interaction Study for EYP001 With EntecavirClinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B PatientsContinuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNAA Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-InfectionEffect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) InfectionHBsAg Related Response Guided TherapyClinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy SubjectsTenofovir Alafenamide Versus Tenofovir Alafenamide Plus Entecavir in Patients With Entecavir-resistant Acute Exacerbation of Chronic Hepatitis BThe Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical TrialTenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus TenofovirTacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) TrialsInduction of Fibrosis Regression on Patients With Chronic Hepatitis B InfectionTherapeutic Hepatitis B Vaccine (Synthesized Peptide εPA-44) Joint Entecavir in Treating Chronic Hepatitis B PatientsPegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis BLong-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis BA Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding BiomarkersEfficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced PatientsA Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis BThe Effect of Entecavir Consolidation on Post-TDF Treatment DurabilityOptimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B PatientsTenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis BA Study in Healthy Volunteers and Patients With Chronic Hepatitis B (2016-11-30)Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus InfectionA Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (2019-11-06)A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With EntecavirA RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative ResectionA RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative ResectionA Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus InfectionNUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC
P4844
Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patientsEntecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
P921
Q61729655-A7BBB3C9-F57E-4825-A220-5565A0D7C0A9Q61908859-B1979D82-B4B2-4CCA-AE42-B422D21EBEF4Q61915211-A0EDA2E0-269D-45F1-AEA9-F8C5F6C35B07Q61921648-FC626B10-E0CE-44EC-8EFE-E3ACA3D91A1BQ61933205-0584C098-3966-420F-8E0E-9B17AC77C681Q61966066-26F3BA3E-2F29-42CF-AE85-B616FF7E43C1Q62055006-5E82942F-E2A7-43E7-BE4D-6162610D59A4Q62062224-F4B9D1BE-F6E5-4264-88BD-BB7D28E38714Q62062921-30257F4D-478C-4254-95F3-4FABFFD16DABQ62821293-0B3F807A-C477-4650-9BDF-B49D22EC07D2Q63011197-7648921F-FB4D-4B48-914F-8AA7AD805CE9Q63229746-82C18953-824F-454A-A9DB-9C9C7F594C46Q63335597-E14811FF-0C70-484F-B412-026339EA6609Q63338027-55A81415-981F-4FBA-9EE4-2EE74B503F7EQ63338937-784AF99F-E97A-443C-B064-6CFD3B8810BCQ63340057-4E3A1E73-804A-48D3-8B1F-1974CFCE334AQ63340103-418A9E66-B21C-4BE7-952C-6ECE69DB99B5Q63397758-32F5CD71-062C-43D2-BD73-B73FC1D88B66Q63401200-AA0AF07E-8B70-4023-8A1B-A182B0F46938Q63401437-84659170-B1EC-4A26-B127-A7BF11292C9EQ63572359-0A490A3E-44DA-4E2E-8480-78F66217605FQ63596556-06439170-93E7-4064-9DC5-0AC44AACF475Q63805594-15B7D544-9E88-43F2-941E-28DA4DC2B8E7Q86154706-E73F0830-5037-4D00-9A55-574EC3F7D113Q87078169-7FD70831-8E01-43F1-884A-31E8C476DF7DQ87079121-D399EC1A-69C6-40F8-9758-27E779B09DB7Q92391977-8718C68D-0EFF-4B0D-96BB-DFE3CA5DD603Q94934680-ED783C9E-FA6F-4A2E-A4C8-D175B7682183Q94934681-3C9D342C-3D27-4AD3-8138-0B6C673F04BBQ95056334-537645F5-5C5A-403E-9C50-133D98B1F852Q95719966-43E67570-4A32-4343-98AD-FEF8146C58F4
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Entecavir
@de
Entecavir
@es
Entecavir
@id
Entecavir
@it
Entecavir
@vi
Entekaviiri
@fi
Entekavir
@sh
Entekavir
@sl
Entekavir
@sr
entecavir
@en
type
label
Entecavir
@de
Entecavir
@es
Entecavir
@id
Entecavir
@it
Entecavir
@vi
Entekaviiri
@fi
Entekavir
@sh
Entekavir
@sl
Entekavir
@sr
entecavir
@en
altLabel
Anhydrous entecavir
@en
BMS-200475-01
@en
Baraclude
@de
Entecavir (anhydrous)
@en
Entecavir anhydrous
@en
Entecavir
@en
Entecavirum
@en
SQ-34676
@en
prefLabel
Entecavir
@de
Entecavir
@es
Entecavir
@id
Entecavir
@it
Entecavir
@vi
Entekaviiri
@fi
Entekavir
@sh
Entekavir
@sl
Entekavir
@sr
entecavir
@en
P31
P592
P6366
P646
P661
P662
P665
P683
P1579
P2017
C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2NC(=NC3=O)N
P2067
277.117489